quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:35:00·115d
PRRelease
SELLAS Life Sciences Group Inc. logo

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

SLS· SELLAS Life Sciences Group Inc.
Health Care
Original source

Companies

  • SLS
    SELLAS Life Sciences Group Inc.
    Health Care

Recent analyst ratings

  • Jul 21UpdateCantor Fitzgerald$18.00

Related

  • SEC13h
    SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.
  • SEC13h
    SEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.
  • SEC34d
    SEC Form S-3ASR filed by SELLAS Life Sciences Group Inc.
  • SEC35d
    SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR35d
    SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
  • SEC35d
    SEC Form 10-K filed by SELLAS Life Sciences Group Inc.
  • PR37d
    SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022